AusCann Effects Board Changes
4 November 2019 – Leading medical cannabis company AusCann Group Holdings
Limited (ASX:AC8) (AusCann or ‘the Company’) announces that further to the Board
renewal process announced on 28 October 2019, the Company has appointed Mr Christopher
Mews as a Non-Executive Director of AusCann. Mr Mews is the nominee from AusCann’s
largest shareholder, Merchant Funds Management, with his appointment to be effective from
1 December 2019.
Mr Mews is an experienced non-executive director with over 20 years in the financial services
sector, having held senior positions in finance, corporate secretarial and compliance in listed
and unlisted companies.
Mr Mews is currently the Chief Financial Officer and Company Secretary of Merchant Group
Pty Ltd, a Perth based financial services firm that provides funds management and corporate
finance services, with investment experience both in Australia and internationally in the
medical cannabis sector. Prior to Merchant Group, he was the Chief Financial Officer and
Company Secretary of listed biotech Company Polynovo Limited (ASX:PNV), and is currently
Company Secretary and Non-Executive Director of VPCL Limited (ASX:VPC).
Mr Mews holds a Bachelor of Business majoring in Accounting and is a Certified Practising
Accountant, a Chartered Company Secretary and member of the Governance Institute of
The Company also advises that Dr Paul MacLeman has resigned as an Executive Director of
AusCann effective today. Dr MacLeman joined the AusCann Board as a part of the CEO
leadership transition in late 2018, and with that transition to the Company’s new CEO Mr
Ido Kanyon having now taken place, it is appropriate for him to step down. The Board thanks
Dr MacLeman for standing in as interim CEO and Director during this important transition